A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer

Journal of the National Cancer Institute

Volumn 109, Issue 11, 2017, Pages

  Goldstein, Daniel A ^a,b   Gordon, Noa ^a,c   Davidescu, Michal ^d   Leshno, Moshe ^e   Steuer, Conor E ^b   Patel, Nikita ^b   Stemmer, Salomon M ^a,e   Zer, Alona ^a,e  

^a RABIN MEDICAL CENTER   (Israel)

^b EMORY UNIVERSITY   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d CLALIT HEALTH SERVICES   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; PEMBROLIZUMAB; PEMETREXED; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ARTICLE; BUDGET; BUDGET IMPACT ANALYSIS; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECOG PERFORMANCE STATUS; EGFR GENE; FIRST-LINE TREATMENT; FOLLOW UP; GENE; GENE MUTATION; HUMAN; KAPLAN MEIER METHOD; LUNG METASTASIS; MEDICARE; MELANOMA; MONTE CARLO METHOD; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERSONALIZED CANCER THERAPY; PHARMACOECONOMICS; PRICE; PROGRESSION FREE SURVIVAL; REIMBURSEMENT; SENSITIVITY ANALYSIS; SMALL CELL LUNG CANCER; SURVIVAL RATE; SYSTEMIC THERAPY; UNITED STATES; BODY WEIGHT; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; DOSE CALCULATION; ECONOMICS; LUNG NEOPLASMS; METABOLISM; MORTALITY; PATHOLOGY; PERSONALIZED MEDICINE; SECONDARY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BODY WEIGHT; BUDGETS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG COSTS; DRUG DOSAGE CALCULATIONS; HUMANS; LUNG NEOPLASMS; MONTE CARLO METHOD; PRECISION MEDICINE; UNITED STATES;

EID: 85033608211     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djx063     Document Type: Article

References (32)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7–30.
2. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016; 375(19):1823–1833.
3. Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21(19):4286–4293.
4. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014; 384(9948):1109–1117.
5. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–918.
6. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028.
7. Chatterjee M, Turner DC, Felip E, et al. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann Oncol. 2016;27(7):1291–1298.
8. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet. 2016;387(10027): 1540–1550.
9. Centers for Disease Control and Prevention: Faststats. http://www.cdc.gov/nchs/fastats. Accessed November 16, 2016.
10. Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5–14.
11. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2013. Bethesda, MD: National Cancer Institute; 2013.
12. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006; 24(28):4539–4544.
13. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9): 2892–2911.
14. Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: An analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013;19(15):4273–4281.
15. Goulart BH, Reyes CM, Fedorenko CR, et al. Referral and treatment patterns among patients with stages III and IV non-small-cell lung cancer. J Oncol Pract. 2013;9(1):42–50.
16. Cohen MH, Justice R, Pazdur R. Approval summary: Pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer. Oncologist. 2009;14(9):930–935.
17. Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33(30):3488–3515.
18. Lagarias JL, Reeds JA, Wright MH, et al. Convergence properties of the Nelder–Mead simplex method in low dimensions. SIAM J Optimiz. 1998;9(1): 112–147.
19. de Greef R, Elassaiss-Schaap J, Chatterjee M, et al. Pembrolizumab: Role of modeling and simulation in bringing a novel immunotherapy to patients with melanoma. CPT Pharmacometrics Syst Pharmacol. 2017;6(1):5–7.
20. Freshwater TSJ, de Grieef R, Kondic A, et al. Assessment of pembrolizumab (MK-3475) dosing strategy based on population pharmacokinetics and exposure-response models. J Pharmacokinet Pharmacodyn. 2015;42(11):S15.
21. Garon EB, Reck M, Rodriguez-Abreu D, et al. Use of a 200-mg fixed dose of pembrolizumab for the treatment of advanced non–small cell lung cancer (NSCLC) (ID 6129). In: 17th World Conference on Lung Cancer. Vienna, Austria: International Association for the study of lung cancer (IASLC); 2016.
22. Robert C, Ribas A, Hamid O, et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. J Clin Oncol. 2016;34(suppl); abstr 9503.
23. Modification of the dosage regimen for nivolumab. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm520871.htm. Accessed October 10, 2016.
24. Bach PB, Conti RM, Muller RJ, et al. Overspending driven by oversized single dose vials of cancer drugs. BMJ. 2016;352:i788.
25. Office of Inspector General Work Plan. In: US Department of Health and Human Services; 2017. https://oig.hhs.gov/reports-and-publications/archives/workplan/2017/HHS%20OIG%20Work%20Plan%202017.pdf Accessed November 13, 2016.
26. Pembrolizumab (KEYTRUDA) checkpoint inhibitor. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm526430.htm. Accessed October 26, 2016.
27. Bach PB. Indication-specific pricing for cancer drugs. JAMA. 2014;312(16): 1629–1630.
28. Goldstein DA, Chen Q, Ayer T, et al. Necitumumab in metastatic squamous cell lung cancer: Establishing a value-based cost. JAMA Oncol. 2015;1(9): 1293–1300.
29. Prasad V, Wang R, Afifi SH, et al. The rising price of cancer drugs—a new old problem? JAMA Oncol. 2016; in press.
30. ASP drug pricing files. https://www.cms.gov/medicare/medicare-fee-for-service-part-b-drugs/mcrpartbdrugavgsalesprice/2016aspfiles.html. Accessed November 13, 2016.
31. Nutrition, physical activity and obesity data. Trends and maps web site. http://www.cdc.gov/nccdphp/dnpao/index.html. Accessed October 25, 2016.
32. Warren JL, Butler EN, Stevens J, et al. Receipt of chemotherapy among Medicare patients with cancer by type of supplemental insurance. J Clin Oncol. 2015;33(4):312–318.